Multiple Myeloma (MM)
Bortezomib and dexAMETHasone Therapy
Indication
00270a
Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy.
Bortezomib Maintenance Therapy - 14 day
Bortezomib, Lenalidomide and dexAMETHasone (RVD) Therapy-21 day
Indication
00416a
Treatment of newly diagnosed myeloma in adult patients with high risk features.
00416b
Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features.
Bortezomib, Lenalidomide and dexAMETHasone (RVD) Therapy- 28 day
Bortezomib, Melphalan and prednisoLONE Therapy
Indication
00275a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib, Lenalidomide and dexAMETHasone (RVD-Lite) Induction Therapy
Indication
00780a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible.
Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy
Indication
00781a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.
Lenalidomide Maintenance Therapy (RVD-Lite)
Indication
00782a
Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.
Bortezomib, Thalidomide and dexAMETHasone (VTD) Induction Therapy
Indication
00274a
Bortezomib, thalidomide and dexAMETHasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Carfilzomib and dexAMETHasone (Kd) Therapy-28day
Indication
00566a
Carfilzomib in combination with dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Carfilzomib (20/70mg/m2 once Weekly) dexAMETHasone (Kd) Therapy-28 day
Indication
00595a
Carfilzomib in combination with dexAMETHasone is indicated for
the treatment of adult patients with multiple myeloma who
have received at least one prior therapy
Carfilzomib (56mg/m2 once weekly) Lenalidomide and dexAMETHasone (KRd) Therapy - 28 day
Indication
00598a
Carfilzomib, lenalidomide and dexAMETHasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Carfilzomib (27mg/m2 twice weekly), Lenalidomide and dexAMETHasone (KRd) Therapy - 28 day
Indication
00405a
Carfilzomib, lenalidomide and dexAMETHasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
CyBorD/ cycloPHOSphamide, Bortezomib, and dexAMETHasone-21 day Therapy
Indication
00273a
Treatment of newly diagnosed symptomatic multiple myeloma
00273b
Treatment of relapsed/refractory multiple myeloma
Modified CyBord/ Bortezomib/ cycloPHOSphamide and dexAMETHasone – weekly therapy
Indication
00299a
Treatment of newly diagnosed symptomatic multiple myeloma.
00299b
Treatment of relapsed/refractory multiple myeloma.
Daratumumab Monotherapy
Indication
00426a
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Daratumumab S/C Monotherapy
Indication
00604a
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy
Daratumumab (IV), Bortezomib and dexAMETHasone Therapy
Indication
00560a
Daratumumab in combination with bortezomib and dexAMETHasone in adult patients with multiple myeloma who have received at least one prior therapy
Daratumumab (SC 1800mg), Bortezomib and dexAMETHasone Therapy
Indication
00609a
Daratumumab in combination with bortezomib and dexAMETHasone in adult patients with multiple myeloma who have received at least one prior therapy
Daratumumab (SC 1800mg), Bortezomib (weekly) and dexAMETHasone Therapy
Indication
00695a
Daratumumab in combination with bortezomib and dexAMETHasone in adult patients with multiple myeloma who have received at least one prior therapy
Daratumumab SC, Bortezomib, Thalidomide and dexAMETHasone Induction Therapy
Indication
00703a
Daratumumab in combination with bortezomib, thalidomide and dexAMETHasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Daratumumab SC, Bortezomib, Thalidomide and dexAMETHasone Consolidation Therapy
Indication
00755a
Daratumumab in combination with bortezomib, thalidomide and dexAMETHasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and dexAMETHasone Induction Therapy
Indication
00752a
Daratumumab in combination with bortezomib, thalidomide and dexAMETHasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and dexAMETHasone Consolidation Therapy
Indication
00756a
Daratumumab in combination with bortezomib, thalidomide and dexAMETHasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Elranatamab Monotherapy
Indication:
00917a
As monotherapy for the treatment of adult patients with relapsed and refractory (R/R) multiple myeloma (MM), who have received at least three prior therapies including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-cluster of differentiation 38 (anti-CD38) antibody and have demonstrated disease progression on the last therapy.
Ixazomib, Lenalidomide and dexAMETHasone Therapy - 28 day
Indication
00516a
Ixazomib in combination with lenalidomide and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Lenalidomide 25mg and dexAMETHasone Therapy-28 day
Indication
00218a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
00218b
Treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Pomalidomide and dexAMETHasone
Indication
00245a
Treatment in combination with dexAMETHasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Pomalidomide, Bortezomib and dexAMETHasone (PVD) Therapy
Indication
00601a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
Pomalidomide, Bortezomib (Once weekly) and dexamethasone (PVD) - 28 day Therapy
Indication
00880a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy
Indication
00496a
Failure to achieve response or disease progression with induction therapy in patients with multiple myeloma.
00496b
Relapsed or refractory myeloma patients suitable for intensive salvage chemotherapy.
00496c
Treatment of multiple myeloma in patients with primary plasma cell leukaemia or initial presentation with extra-medullary disease.
Daratumumab SC, Lenalidomide and dexAMETHasone Therapy
Indication
00854a
Daratumumab in combination with lenalidomide and dexAMETHasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Talquetamab Monotherapy (biweekly)
Indication
00914a
As monotherapy for the treatment of adult patients with relapsed and refractory (R/R) multiple myeloma (MM), who have received at least three prior therapies including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-cluster of differentiation 38 (anti-CD38) antibody and have demonstrated disease progression on the last therapy.
Teclistamab Monotherapy
Indication
00865a
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including and immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Teclistamab Monotherapy - Two Weekly Maintenance
Indication
00927a
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Amyloidosis
Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy
Indication
00779a
Daratumumab in combination with bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28 Day Therapy
Indication
00652a
Treatment of newly diagnosed systemic AL amyloidosis
00652b
Treatment of relapsed/refractory systemic AL amyloidosis
Plasma Cell Disorder Other (Mobilisation of peripheral blood stem cells, conditioning regimens for MM and plasma Cell dyscrasia)
cycloPHOSphamide 2000mg/m2 For Stem Cell Mobilisation
Indication
00438a
Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy
cycloPHOSphamide 1500mg/m2 For Stem Cell Mobilisation
Indication
00795a
Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy.
High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant
Indication
00454a
Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant
00454b
Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis
Plerixafor and G-CSF Therapy
Indication
00536a
Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly